At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 302 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab, Ustekinumab, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 302 participants across 48 sites in 13 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesAustria, Belgium, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionMay 2016
Study CompletionOct 2017
TodayJul 2026
First PostedSep 28, 2015
Enrollment StartOct 1, 2015
Primary CompletionMay 1, 2016
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.8 years ago
Interventions
Ixekizumabdrug
Administered SC
Ustekinumabdrug
Administered SC
Placebodrug
Administered SC